Amgen, Inc. (AMGN)

HEALTH CARE: PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

ONE AMGEN CENTER DRIVE THOUSAND OAKS, CA 91320

Amgen Inc. (Amgen) is an independent biotechnology medicines company. The Company discovers, develops, manufactures and markets medicines for grievous illnesses. It focuses on human therapeutics and concentrates on medicines based on advances in cellular and molecular biology. Its principal products include Aranesp (darbepoetin alfa) and EPOGEN (Epoetin alfa), erythropoietic-stimulating agents (ESAs) that stimulate the production of red blood cells; Neulasta (pegfilgrastim), a pegylated protein, based on the Filgrastim molecule, and NEUPOGEN (Filgrastim), a recombinant-methionyl human granulocyte colony-stimulating factor (G-CSF), both of which selectively stimulate the production of neutrophils (a type of white blood cell that helps the body fight infection), and Enbrel (etanercept), an inhibitor of tumor necrosis factor (TNF), a substance that plays a role in the body's response to inflammatory diseases.

Data based on most recent fiscal year report
Market Cap122.113 Billion Shares Outstanding725.91 Million Avg Volume5.617 Million
1-Yr BETA vs S&P TR Current Ratio5.49 Quick Ratio5.17
View SEC Filings from AMGN instead.
Q3 2018 All Institutions Hedge Funds 1
To trade AMGN now:
Filers who had this stock in their top 10: 103 14 (1.35%)
13F Filers holding this stock: 1744 124 (11.97%)
Aggregate 13F shares on 09/30/2018: 489.579 Million 21.263 Million
Aggregate 13F shares on 06/30/2018: 535.438 Million 20.006 Million
Percent change: -8.56% 6.28%
Funds creating new positions: 106 17
Funds Adding to an existing position: 592 41
Funds closing out their position: 66 16
Funds reducing their position: 775 52
Heat Map Ranking for 09/30/2018 5
Heat Map Ranking for 06/30/2018 81
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding AMGN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to

Exclude:

Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

1.8 Thousand total shares from 1 transactions

Exercise Derivative Conversion (M)

8.3 Thousand total shares from 2 transactions

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Acquired or Disposed Shares Owned Following Transaction Direct/Indirect Ownership

PIACQUAD DAVID - Officer SVP, BUSINESS DEVELOPMENT

2018-11-30 M 6,500 a 45,128 direct

PIACQUAD DAVID - Officer SVP, BUSINESS DEVELOPMENT

2018-11-30 M 6,500 d 0 direct

PIACQUAD DAVID - Officer SVP, BUSINESS DEVELOPMENT

2018-11-30 F 4,109 d 41,019 direct

PATTON CYNTHIA M - Officer SVP & CCO

2018-11-29 M 1,777 a 23,090 direct

PATTON CYNTHIA M - Officer SVP & CCO

2018-11-29 M 1,777 d 0 direct

PATTON CYNTHIA M - Officer SVP & CCO

2018-11-29 S 1,777 d 21,313 direct

HOLLEY CHARLES M - Director

2018-11-05 A 93 a 1,427 direct

GORDON MURDO - Officer EVP GLOBAL COMMERCIAL OPS

2018-11-02 A 34,213 a 34,213 direct

KULLMAN ELLEN JAMISON - Director

2018-11-02 A 149 a 3,312 direct

REESE DAVID M - Officer EVP, RESEARCH AND DEVELOPMENT

2018-11-02 A 12,830 a 30,618 direct
Click here to report any possible errors with this stock listing.

Elevate your investments